A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2006
12/21/2006	US20060286102 Cell surface receptor isoforms and methods of identifying and using the same
12/21/2006	US20060286101 Administering an anti-CD23 antibody and cyclophosphamide; B cell chronic lymphocytic leukemia
12/21/2006	US20060286100 Use of CD23 Antagonists for the Treatment of Neoplastic Disorders
12/21/2006	US20060286099 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
12/21/2006	US20060286098 Derived from cocaine linked to cholera B toxin; antibodies; for treatment of cocaine addiction; immunization
12/21/2006	US20060286097 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
12/21/2006	US20060286096 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
12/21/2006	US20060286095 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
12/21/2006	US20060286094 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
12/21/2006	US20060286093 secreted tumor necrosis factor receptor polypeptides; modulates B cell activation; inhibiting ztnf4 activity
12/21/2006	US20060286092 Methods of using pNKp30, a member of the B7 family, to modulate the immune system
12/21/2006	US20060286091 RelA-ASSOCIATED INHIBITOR, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF
12/21/2006	US20060286090 Mediators of epithelial adhesion and their role in cancer and skin disorders
12/21/2006	US20060286089 Compositions and methods for the treatment of burns and sepsis
12/21/2006	US20060286079 Use of cytokines and mitogens to inhibit pathological immune responses
12/21/2006	US20060286075 Method and compositions for treating hepatocellular cancer
12/21/2006	US20060286067 Methods for making and using regulatory T cells
12/21/2006	US20060286066 Pegylated immunoglobulin variable region polypeptides
12/21/2006	US20060286035 Methods and compositions for modulating the interaction between adiponectin and its receptor
12/21/2006	US20060286031 Modulators of tissue regeneration
12/21/2006	US20060286030 an antigen binding fragment comprising a heavy chain and a light chain variable region amino acid sequences, associated to effector cells for triggering antibody-dependent cell-mediated cytotoxicity (ADCC) mechanisms; useful for inhibiting proliferation and/or killing melanoma cells
12/21/2006	CA2612271A1 Vaccines for immunization against helicobacter
12/21/2006	CA2612180A1 Methods of treatment, and diagnosis of epilepsy by detecting mutations in the scn1a gene
12/21/2006	CA2612069A1 Antigen conjugates and uses thereof
12/21/2006	CA2611954A1 Dengue serotype 2 attenuated strain
12/21/2006	CA2611054A1 Novel a.beta.-binding protein and its peptide derivatives and uses thereof
12/21/2006	CA2611023A1 Use of panton-valentine leukocidin for treating and preventing staphylococcus infections
12/21/2006	CA2610919A1 Hepatitis c virus nucleic acid vaccine
12/21/2006	CA2610277A1 Highly attenuated pox virus strains, method for the production thereof and the use thereof as paramunity inducers or for producing vector vaccines
12/21/2006	CA2578844A1 Semi-soft c-class immunostimulatory oligonucleotides
12/21/2006	CA2574848A1 Antagonizing interleukin-21 receptor activity
12/21/2006	CA2574090A1 Methods and compositions for inducing innate immune responses
12/20/2006	EP1734368A2 Annexins and autoantibodies used as markers for cancer
12/20/2006	EP1734133A2 Heparanase specific molecular probes and their use in research and medical applications
12/20/2006	EP1734122A2 APO-2 ligand
12/20/2006	EP1734051A2 Composition and methods for the diagnosis of tumours
12/20/2006	EP1734050A2 Immunization of dairy cattle with GapC protein against streptococcus infection
12/20/2006	EP1733743A1 Preventives/remedies for cancer
12/20/2006	EP1733740A1 Therapeutic agent for auris interna disorder containing il-6 antagonist as active ingredient
12/20/2006	EP1733737A1 Axon regeneration promoter
12/20/2006	EP1733736A2 Method of producing recombinant antibodies against tumours
12/20/2006	EP1733735A2 Methods and products for inducing mucosal immunity
12/20/2006	EP1733237A2 Diagnostics and therapeutics for diseases associated with peroxisome proliferative activated receptor alpha (ppara)
12/20/2006	EP1733041A2 Anti-myostatin antibodies
12/20/2006	EP1732950A2 Antibodies to erythropoietin receptor and uses thereof
12/20/2006	EP1732949A2 Methods for treating bone cancer pain by administering a nerve growth factor antagonist
12/20/2006	EP1732948A2 Therapeutic synergy of anti-cancer compounds
12/20/2006	EP1732650A1 Composition and method for cancer treatment
12/20/2006	EP1732648A2 Treatment of diseases
12/20/2006	EP1732608A2 Folate conjugates and complexes
12/20/2006	EP1732603A1 Cytotoxicity mediation of cells evidencing surface expression of cd63
12/20/2006	EP1732602A1 Cytotoxicity mediation of cells evidencing surface expression of mcsp
12/20/2006	EP1732601A1 Cytotoxicity mediation of cells evidencing surface expression of cd44
12/20/2006	EP1732600A2 Uses of anti-ctla-4 antibodies
12/20/2006	EP1732599A1 Use of emmprin antagonists for the treatment of diseases associated with excessive angiogenesis
12/20/2006	EP1732598A2 Inducing cellular immune responses to human papillovirus using peptide and nucleid acid compositions
12/20/2006	EP1732597A2 Streptococcus agalactiae vaccine
12/20/2006	EP1732596A2 Therapeutic use of rm1 antigen
12/20/2006	EP1732595A2 Identification of self and non-self antigens implicated in autoimmune diseases
12/20/2006	EP1732594A2 Method for the delivery of sustained release agents
12/20/2006	EP1732591A2 Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer
12/20/2006	EP1732588A2 Modulation of nkg2d
12/20/2006	EP1732585A1 Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins
12/20/2006	EP1732584A2 Multi-component biological transport systems
12/20/2006	EP1732581A2 Polypeptide transduction and fusogenic peptides
12/20/2006	EP1732580A2 Epha2 vaccines
12/20/2006	EP1732382A2 Sfec, a sperm flagellar energy carrier protein
12/20/2006	EP1519745B1 Method to enhance an immune response of nucleic acid vaccination
12/20/2006	EP1442124B1 Polypeptide antigen forming a mimetic structure of the gp41 intermediate state
12/20/2006	EP1379556B1 Anti pilyrosporum ovale igy and its uses
12/20/2006	EP1233058B1 Method of proliferating natural killer cells
12/20/2006	EP1194164B1 Prion protein peptides and uses thereof
12/20/2006	EP1135477B1 Humanized monoclonal integrin antibodies
12/20/2006	EP1124579B1 Method and apparatus for producing a composite product
12/20/2006	EP0942983B1 Streptococcus pneumoniae antigens and vaccines
12/20/2006	EP0833660B1 Vectors for the diagnosis and treatment of solid tumors including melanoma
12/20/2006	CN1882612A Hypo- and hyper-acetylated meningococcal capsular saccharides
12/20/2006	CN1882609A Altering a B cell pathology using self-derived antigens in conjunction with specific-binding cytoreductive agent
12/20/2006	CN1882603A mRNA transfected antigen presenting cells
12/20/2006	CN1882360A The use of antibiotics as vaccine adjuvants
12/20/2006	CN1882359A Pharmaceutical compositions for therapeutic use
12/20/2006	CN1882358A Vaccine composition admixed with an alkylphosphatidylcholine
12/20/2006	CN1880457A Ad6重组核酸 Ad6 recombinant nucleic acid
12/20/2006	CN1880448A Infectious bursal disease virus VP2 gene expressed recombinant newcastle disease LaSota attenuated vaccine strain
12/20/2006	CN1879881A Yeast vaccine production method
12/20/2006	CN1879880A Use of immunological stimulant compoundú¿ISCOMsú®in fish immunity by oral administration and dipping bath method
12/20/2006	CN1291012C Altered strain of modified vaccinia virus ankara (MVA)
12/20/2006	CN1290866C Anthrax toxin acceptor ATR-Fc fusion protein
12/20/2006	CN1290864C Ant CD20 chimeric antibody
12/20/2006	CN1290580C Chick lecithal immune globulin products against rolavirus
12/20/2006	CN1290579C Recombinant foot-and-mouth disease virus VP1 confluent protein vaccine
12/20/2006	CA2549086A1 Chimeric polypeptides and their therapeutic applications against a flaviviridae infection
12/20/2006	CA2508266A1 Chimeric polypeptides and their therapeutic application against a flaviviridae infection
12/19/2006	USRE39433 Therapeutic agents as cytokine antagonists and agonists
12/19/2006	US7151172 virion infectivity factor (vif) proteins; use in vaccine against the HIV-1 virus
12/19/2006	US7151171 Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
12/19/2006	US7151169 For therapy of fibrosis, immune responses and tumor progression, asthma
12/19/2006	US7151164 Genetic engineered, chimera and human monoclonal antibodies that bind to lymphocytes CD antigens, used for diagnosis and prohylaxis of cancer and autoimmune diseases
12/19/2006	US7151163 Antiviral agents for the treatment, control and prevention of infections by coronaviruses
12/19/2006	US7151159 Amino acid sequences for therapeutic and prophylactic use against diseases due to clostridium difficile toxins

1 ... 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 ... 1823